Daily chewable tadalafil and vardenafil for ED is a different clinical idea from the standard, higher-dose pill taken shortly before sex. Instead of creating a narrow treatment window, a maintenance formulation aims to keep phosphodiesterase type 5 (PDE5) inhibition present at lower intensity throughout the week, while adding a micronutrient layer that may be relevant in men with vascular risk or documented deficiency. That does not mean every man needs daily therapy, and it certainly does not mean more ingredients automatically translate to better outcomes. It means the formulation should be judged by pharmacology, patient selection, and the quality of the evidence supporting each component.
What a maintenance formulation is trying to solve
Most first-line erectile dysfunction treatment is built around convenience and immediacy. A man takes an on-demand PDE5 inhibitor, waits for absorption, and expects a response during a relatively defined period of sexual activity. For many patients, that works well. For others, it creates familiar friction: timing pressure, variable response after heavy meals or alcohol, a sense that every encounter has to be scheduled, and uncertainty about whether the medication will feel reliable enough on that day.
A daily formulation is designed around a different problem. It is not trying to create the strongest possible short-term peak. It is trying to support a steadier baseline of erectile readiness and reduce the need to choreograph sex around dosing. That shift is clinically relevant because many men with ED are not dealing with a purely situational problem. They are dealing with endothelial dysfunction, hypertension, insulin resistance, poor sleep, obesity, medication effects, or age-related decline in vascular responsiveness. In that setting, maintaining low-dose PDE5 exposure may make more physiological sense than repeating high-dose, episodic treatment.
The other reason maintenance strategies attract interest is adherence. Men are more likely to stay with treatment when it fits ordinary life. If the regimen is discreet, easy to take, and less dependent on precise timing, some men experience less anticipatory stress and more consistent use, which can matter as much as raw efficacy.
Why daily chewable tadalafil and vardenafil for ED differs from on-demand dosing
Tadalafil is the anchor of most daily ED strategies because its long half-life allows relatively stable drug exposure over time. That is why the 5 mg once-daily dose has become the most familiar maintenance PDE5 approach. In a 2024 randomized controlled study, Bakry and colleagues compared daily tadalafil 5 mg with daily sildenafil 25 mg over two months and found similar clinical improvement in erectile function, while tadalafil was associated with greater reduction in inflammatory markers such as neutrophil-lymphocyte and platelet-lymphocyte ratios [1]. That does not prove an anti-inflammatory treatment effect in every patient, but it strengthens the broader case for daily tadalafil as more than a simple timing substitute.
Formulation may matter as well. A 2024 placebo-controlled trial by Motawi and colleagues evaluated tadalafil 5 mg delivered as a tablet versus an oral dispersible film in men with mild-to-moderate ED. Both active tadalafil groups improved erectile function compared with placebo, and the dispersible film performed well on efficacy, tolerability, and compliance measures [2]. A chewable or rapidly dispersing format is not automatically superior, but these data support the idea that alternative oral delivery systems can be clinically reasonable when a daily regimen is the goal.
The key distinction, then, is not merely dose. It is the treatment model. On-demand therapy concentrates effect around a planned encounter. Daily therapy tries to reduce the gap between sexual readiness and medication timing. For men who dislike the stop-start rhythm of as-needed dosing, that difference can be meaningful.
Why add a second PDE5 inhibitor at a low dose
The most distinctive part of this formulation is the addition of vardenafil 5 mg alongside tadalafil 5 mg. On paper, that sounds like redundancy because both drugs inhibit PDE5. In practice, the rationale is subtler. Tadalafil and vardenafil are not identical molecules, and they do not behave identically in terms of onset profile, half-life, and selectivity across related phosphodiesterase enzymes. A low-dose dual approach is intended to widen pharmacologic coverage without simply escalating one agent toward a higher, more side-effect-prone peak.
This is an area where caution matters. The literature is far stronger for established single-agent PDE5 therapy than for routine unsupervised dual-PDE5 use. Clinical reasoning here depends on formulation design, medical screening, and an understanding that low-dose combination therapy is not the same as stacking random high doses at home. The goal is not maximal short-term intensity. The goal is broader daily support in men who may benefit from both tadalafil's long background window and vardenafil's complementary pharmacology.
This is also why physician supervision is not optional. Men taking nitrates cannot use PDE5 inhibitors. Care is also needed with certain alpha-blockers, substantial hypotension, unstable cardiovascular disease, recent stroke or myocardial infarction, retinal disorders, and prior intolerance to PDE5 therapy. A combination maintenance formula only makes sense when those risks have already been screened.
The nutrient layer, what vitamin D3 and K2 may add, and what they do not prove
A daily chewable formulation in this category commonly adds vitamin D3 and vitamin K2 to the PDE5 backbone. The logic is not that vitamins "fix" ED on their own. The logic is that erectile function is tightly linked to vascular health, endothelial signaling, and, in some men, hormonal context. Vitamin D deficiency is common, and observational research has repeatedly associated lower vitamin D status with worse erectile function, especially in men with moderate-to-severe or arteriogenic ED.
That association was summarized in a 2025 systematic review by Matukaitienė and colleagues, which pooled data from over 13,000 men. The authors concluded that lower vitamin D levels were consistently associated with more severe erectile dysfunction in observational studies, while also emphasizing that the evidence remains low certainty and that randomized trial results are mixed [4]. That balance matters. Clinical studies suggest vitamin D status may support endothelial and sexual health, but the evidence does not justify presenting vitamin D as a stand-alone ED therapy.
In fact, the largest recent randomized test of supplementation points in the other direction. In 2024, Romero and colleagues reported exploratory results from the D-Health Trial, which included 8,920 older men who answered the erectile dysfunction question after three years of vitamin D or placebo. Despite substantially higher serum vitamin D levels in the supplementation group, the prevalence of ED was essentially unchanged between groups [5]. In other words, correcting vitamin D in an unselected population does not appear to prevent or reverse ED by itself.
That nuance is exactly why the nutrient layer should be framed carefully. Vitamin D3 may be reasonable in a formulation intended for men who are deficient or at risk of deficiency, but it should not be oversold. Vitamin K2 is even more indirect. Its rationale centers on calcium handling and vascular biology rather than direct erectile-function evidence. Put simply, there is a plausible systems-level reason to include D3 and K2 in a daily men's health formula, but the strongest direct evidence in this category still belongs to the PDE5 components, not the vitamins.
Who may be a fit for this kind of daily formula
A maintenance-style chewable is not the right first choice for every man with ED. It is more likely to fit men who experience erectile difficulty often enough that on-demand dosing feels cumbersome, men who want less timing pressure, or men who have a reasonably good response to PDE5 therapy but want a steadier baseline. It may also appeal to men with cardiometabolic risk factors, where ED is part of a larger vascular picture rather than an isolated performance problem.
The recent vascular literature supports taking that broader picture seriously. In a large 2025 longitudinal analysis of more than 500,000 men with ED, Jehle and colleagues found that tadalafil and sildenafil use were associated with lower risks of all-cause mortality, myocardial infarction, stroke, venous thromboembolism, and dementia over three years, with tadalafil showing the stronger signal in several analyses [3]. Observational data do not prove causation, and they should not be interpreted as a reason to prescribe PDE5 inhibitors for disease prevention alone. But they do reinforce an important clinical point: ED therapy sits inside cardiovascular medicine, not outside it.
Men who are poor candidates include those using nitrates, men with unstable cardiac status, and anyone considering daily plus on-demand PDE5 use without physician guidance. A daily chewable formula is built for consistency, not improvisation. If a patient needs a different effect profile, the safer answer is dose review or a different physician-guided regimen, not ad hoc stacking.
How to take it and what to monitor
A typical maintenance chewable in this category uses tadalafil 5 mg, vardenafil 5 mg, vitamin D3 200 IU, and vitamin K2 1 mg once daily. The practical advice is simple. Take it at about the same time each day, give it time to build into routine use, and do not assume the first dose tells the whole story. Daily regimens usually need days to weeks, not one isolated encounter, before a patient can judge whether the approach fits his physiology and preferences.
The common adverse effects remain the familiar PDE5 profile: headache, flushing, dyspepsia, nasal congestion, light-headedness, and occasional back pain. Some men experience very little; others find even low-dose daily therapy too noticeable. Food effects are usually less important with tadalafil than with some on-demand regimens, but consistency still helps patients understand what response they are actually getting.
Monitoring should also include expectation management. A daily formula may support more predictable function, but it does not remove the need for arousal, relationship context, sleep, cardiometabolic care, or basic medication review. If ED is worsening despite appropriate use, that is not a signal to keep adding pills. It is a signal to reassess the underlying drivers.
Conclusion
Daily low-dose combination therapy can make clinical sense when the problem is not simply achieving a short-lived effect before one encounter, but building a more reliable baseline with less timing pressure. The evidence is strongest for the tadalafil component and for the general principle that PDE5 therapy belongs within a broader vascular-health framework. The case for adding vitamins is more conditional, especially when deficiency is suspected, and it should be presented with restraint rather than certainty. For more evidence-based reading, visit the blog or review the formulation overview here.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Bakry AR, Mahran A, Elmenyar A, et al. Evaluation of the effect of daily tadalafil 5 mg versus daily sildenafil 25 mg on neutrophil-lymphocyte and platelet-lymphocyte ratios in patients with erectile dysfunction: A comparative randomized controlled study. Archivio Italiano di Urologia e Andrologia. 2024;96(4):12756. doi:10.4081/aiua.2024.12756
- Motawi AT, GamalEl Din SF, Meatmed EM, Fahmy I. Evaluation of efficacy and safety profile of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film in men with mild-to-moderate erectile dysfunction: a comparative placebo-controlled study. International Urology and Nephrology. 2024;56:2531-2537. doi:10.1007/s11255-024-04003-x
- Jehle DVK, Sunesra R, Uddin H, et al. Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia. The American Journal of Medicine. 2025;138(3):441-448.e3. doi:10.1016/j.amjmed.2024.10.039
- Matukaitienė R, Žukauskienė R, Kasparavičius J, et al. The Association Between Vitamin D Levels and Erectile Dysfunction in Men: A Systematic Review. Journal of Clinical Medicine. 2025;14(24):8630. doi:10.3390/jcm14248630
- Romero BD, Waterhouse M, Baxter C, et al. The effect of three years of vitamin D supplementation on erectile dysfunction: Results from the randomized placebo-controlled D-Health Trial. Clinical Nutrition ESPEN. 2024;60:109-115. doi:10.1016/j.clnesp.2024.01.011
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.